Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks Faricimab's Real-World impact on major eye diseases

NCT ID NCT06439576

Knowledge-focused Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study follows 1,000 patients in China who are already receiving faricimab for diabetic macular edema, retinal vein occlusion, or wet age-related macular degeneration. Researchers will collect data from routine clinic visits over one year to see how well the drug works and how safe it is in everyday practice. The goal is to understand real-world treatment patterns and outcomes, not to test a new therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will recruit patients who are naïve to anti-VEGF therapy in the study eye and those who have previously been treated with anti-VEGF therapy in the study eye. Study participation of patients previously treated with other anti-VEGF agents will be capped at a maximum of 40% of each indication enrollment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Have signed the informed consent 2. Female and male Chinese patients, who had been diagnosed with nAMD, DME, or RVO by CFP, OCT, FFA, ICGA, or OCTA 3. ≥50 years old for patients with nAMD, ≥18 years old both for patients with DME and RVO, at the time of signing informed consent (or the first administration of faricimab, whichever occurs first) 4. Patients for whom the decision to receive treatment with faricimab is made prior to and independent from study participation 5. Patients have received at least one faricimab treatment (the first dose) in the study eye Exclusion Criteria: 1. Patients not receiving treatment for nAMD/DME/RVO with faricimab according to the standard of care and in line with the current summary of product characteristics (SPC) / labeling in China 2. Active ocular inflammation or suspected / active ocular infection in either eye 3. Received any other anti-VEGF treatment after faricimab 4. Received any steroid treatment within 6 months (180 days) before the first faricimab treatment in the study eye 5. Any participation in any other clinical trials currently 6. Patients could not provide the clinical data (visual acuity and OCT images) within 2 weeks (14 days) before receiving the initial faricimab injection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic macular edema are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetic macular edema retinal vein occlusion wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic macular edema Neovascular age-related macular degeneration Retinal vein occlusion

Contacts and locations

Locations

  • Affiliated Hospital of Shandong Second Medical University

    Weifang, Shandong, 261031, China

  • Affiliated Hospital of Zunyi Medical University

    Zunyi, 563000, China

  • Dongyang People's Hospital

    Dongyang, 322100, China

  • Eye Hospital of Shandong First Medical University

    Jinan, 250021, China

  • Eye Hospital, Wenzhou Medical University

    Wenzhou, 325027, China

  • Fushun Eye Hospital

    Fushun, Liaoning, 110114, China

  • Guizhou Provincial People's Hospital

    Guiyang, 550002, China

  • Hebei Eye Hospital

    Xingtai, China

  • Hebei People's Hospital

    Shijiazhuang, 050071, China

  • Henan Provincial Eye Hosptial

    Zhengzhou, 450003, China

  • Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)

    Nanjing, 210029, China

  • Jinhua municipal central hospital

    Jinhua, Zhejiang, 321083, China

  • Joint Shantou International Eye Center

    Shantou, Guangdong, 515051, China

  • Panjin Central Hospital

    Panjin, Liaoning, 124010, China

  • Peking University People's Hospital

    Beijing, 100044, China

  • People's Hospital of Dingzhou

    Dingzhou, 73000, China

  • Qingdao Eye Hospital of Shandong First Medical University

    Qingdao, 265299, China

  • Ruijin Hospital Shanghai Jiaotong University School of Medicine

    Shanghai, 200025, China

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, 200080, China

  • Shanghai Tenth People's Hospital

    Shanghai, 200072, China

  • Shanghai Zhoupu Hospital

    Shanghai, China

  • Shanxi Bethune Hospital

    Taiyuan, 030032, China

  • Shenyang Fourth People's Hospital

    Shenyang, 110031, China

  • Shenzhen Eye Hospital

    Shenzhen, 518040, China

  • Sichuan Provincial People's Hospital

    Chengdu, 610072, China

  • Taihe Hospital of Shiyan

    Shiyan, Hubei, 442000, China

  • The Affiliated Hospital of Southwest Medical University, Zhongshan Campus

    Luzhou, China

  • The First Affiliated Hospital of Henan UN of Science and Technology

    Luoyang, Henan, 471000, China

  • The First Affiliated Hospital of Lanzhou University

    Lanzhou, 730000, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, 110001, China

  • The First People's Hospital of Chengdu

    Chengdu, Sichuan, 610016, China

  • The First People's Hospital of Kashgar

    Kashgar, Xinjiang Uygur, 844000, China

  • The First People's Hospital of Yunnan Province

    Kunming, Yun'nan, 650032, China

  • The People?s Hospital of Guangxi Zhuang Autonomous Region

    Nanning, 530021, China

  • Tianjin Eye Hospital

    Tianjin, 300050, China

  • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, 430030, China

  • Xiamen Eye Center Of Xiamen University

    Xiamen, 361000, China

  • Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology

    Wuhan, 430022, China

  • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, 200092, China

  • Xuzhou No.1 Peoples Hospital

    Xuzhou, Jiangsu, 221002, China

  • Zhongshan Ophthalmic Center, Sun Yat-sen University

    Guangzhou, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.